Scott Gottlieb may be stepping down as FDA commissioner next week, but he's still shaping new policy that could have national impact long after he's gone. As part of his congressional farewell tour, he used an FDA budget hearing before a Senate Appropriations subcommittee Thursday to outline aggressive steps the agency should take to combat the U.S. opioid crisis. "We need to be willing to embrace actions in the setting of opioids that we must accept would be unsuitable to any other drug category," Gottlieb said.